KR20240080149A - natural essential oil composition for preventing and treating respiratory diseases by reducing intranasal hazardous microorganism - Google Patents
natural essential oil composition for preventing and treating respiratory diseases by reducing intranasal hazardous microorganism Download PDFInfo
- Publication number
- KR20240080149A KR20240080149A KR1020230167512A KR20230167512A KR20240080149A KR 20240080149 A KR20240080149 A KR 20240080149A KR 1020230167512 A KR1020230167512 A KR 1020230167512A KR 20230167512 A KR20230167512 A KR 20230167512A KR 20240080149 A KR20240080149 A KR 20240080149A
- Authority
- KR
- South Korea
- Prior art keywords
- essential oil
- respiratory diseases
- oil
- complex
- preventing
- Prior art date
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 60
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 244000005700 microbiome Species 0.000 title claims description 11
- 231100001261 hazardous Toxicity 0.000 title 1
- 239000003205 fragrance Substances 0.000 claims abstract description 19
- 239000003921 oil Substances 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 210000003928 nasal cavity Anatomy 0.000 claims description 12
- 206010035664 Pneumonia Diseases 0.000 claims description 10
- 241000207199 Citrus Species 0.000 claims description 4
- 244000178870 Lavandula angustifolia Species 0.000 claims description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 4
- 244000042664 Matricaria chamomilla Species 0.000 claims description 4
- 235000004429 Matricaria chamomilla var recutita Nutrition 0.000 claims description 4
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- 239000001102 lavandula vera Substances 0.000 claims description 4
- 235000018219 lavender Nutrition 0.000 claims description 4
- 239000002304 perfume Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 3
- 244000166124 Eucalyptus globulus Species 0.000 claims description 2
- 244000301850 Cupressus sempervirens Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 241000218691 Cupressaceae Species 0.000 abstract description 16
- 239000000284 extract Substances 0.000 abstract description 8
- 239000005445 natural material Substances 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 abstract 1
- 229940060184 oil ingredients Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- 239000002386 air freshener Substances 0.000 description 2
- 238000000222 aromatherapy Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 244000103926 Chamaenerion angustifolium Species 0.000 description 1
- 235000008302 Chamaenerion angustifolium Nutrition 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/0003—Compounds of unspecified constitution defined by the chemical reaction for their preparation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 사이프러스 에센셜 오일의 제1 에센셜 오일 성분을 필수 성분으로 하는 향을 통한 호흡기 질환 예방 및 치료 복합오일 또는 조성물에 관한 기술로서, 상기 사이프러스 에센셜 오일 이외에 5종의 천연물질의 추출물을 더 포함할 수 있다.
** 본 특허는 (주)노즈바이옴와 산림복지연구개발센터가 공동으로 연구개발한 발명입니다.The present invention relates to a composite oil or composition for preventing and treating respiratory diseases through fragrance containing the first essential oil component of cypress essential oil as an essential ingredient, which may further include extracts of five types of natural substances in addition to the cypress essential oil. You can.
** This patent is an invention jointly researched and developed by Nose Biome Co., Ltd. and the Forest Welfare Research and Development Center.
Description
본 발명은 "향"을 이용한 비강 내 유해 미생물을 감소시키는 기술에 관한 것이다. 특히, 본 발명은 "향"을 이용해 비강 내 유해 미생물을 감소시킴으로써, 폐렴을 포함한 각종 호흡기 질환을 예방 및 치료할 수 있는 조성물에 관한 것이다.The present invention relates to a technology for reducing harmful microorganisms in the nasal cavity using “fragrance.” In particular, the present invention relates to a composition that can prevent and treat various respiratory diseases, including pneumonia, by reducing harmful microorganisms in the nasal cavity using “fragrance.”
본 발명은 폐렴을 포함하는 호흡기 질환의 예방 및 치료 효과가 있는 천연 에센셜 복합오일에 관한 기술로서, 특히, 복용약이나 음식물이 아닌 "향" 치료를 통해 호흡기 질환의 예방 및 치료 효과가 있는 천연 에센셜 복합오일에 관한 기술이다.The present invention relates to a natural essential complex oil effective in preventing and treating respiratory diseases, including pneumonia. In particular, a natural essential complex oil effective in preventing and treating respiratory diseases through “fragrance” treatment rather than oral medication or food. This is a technology related to oil.
천연물을 이용한 호흡기 질환 관련 선행특허를 보면, 특허공개 제10-2014-0131409호에서는 황기, 방풍, 강활, 황금 및 백출의 복합 추출물을 유효성분으로 함유하는, 천식, 기관지염 또는 폐렴의 예방 또는 치료용 약학적 조성물에 관한 기술을 공개하고 있다.Looking at prior patents related to respiratory diseases using natural products, Patent Publication No. 10-2014-0131409 contains complex extracts of Astragalus, Bangpung, Ganghwal, Golden and Baekchul as active ingredients, for the prevention or treatment of asthma, bronchitis or pneumonia. Technology regarding pharmaceutical compositions is disclosed.
특허공개 제10-2021-0042033호에서는 분홍바늘꽃(Epilobium angustifolium L.) 추출물을 유효성분으로 포함하는, 만성폐쇄성폐질환(COPD) 개선용 식품 조성물에 관한 기술을 공개하고 있다.Patent Publication No. 10-2021-0042033 discloses technology regarding a food composition for improving chronic obstructive pulmonary disease (COPD), which contains extract of Epilobium angustifolium L. as an active ingredient.
특허공개 제10-2010-0055030호에서는 황백 추출물을 유효성분으로 함유하는 호흡기 질환의 예방 또는 치료용 약학 조성물에 관한 기술을 공개하고 있다.Patent Publication No. 10-2010-0055030 discloses technology related to a pharmaceutical composition for preventing or treating respiratory diseases containing Hwangbaek extract as an active ingredient.
특허공개 제10-2022-0093743호에서는 인삼 추출물 및 깻잎 추출물의 혼합물인, 미세먼지에 의한 호흡기 질환 예방 또는 치료용 약학 조성물에 관한 기술을 공개하고 있다.Patent Publication No. 10-2022-0093743 discloses technology regarding a pharmaceutical composition for preventing or treating respiratory diseases caused by fine dust, which is a mixture of ginseng extract and perilla leaf extract.
기타 다양한 선행특허문헌에서 천연물질의 추출물을 이용한 호흡기 질환 예방 및 치료용 조성물(약학적 조성물, 식품)을 공개하고 있으나, 위 특허들은 모두 경구용 약품 또는 식품으로 제조되는 기술이다.Various other prior patent documents disclose compositions (pharmaceutical compositions, foods) for preventing and treating respiratory diseases using extracts of natural substances, but all of the above patents are technologies for manufacturing oral drugs or foods.
본 발명은 경구용 의약품이나 식품이 아닌 향을 이용한 호흡기 질환 예방 및 치료 효과가 있는 조성물을 제공하는 것을 목적으로 한다.The purpose of the present invention is to provide a composition that is effective in preventing and treating respiratory diseases using fragrance rather than oral medicine or food.
특히, 본 발명은 합성물질이 아닌 천연물질의 추출물을 이용한 향 치료로서, 호흡기 질환 예방 및 치료 효과가 있는 조성물을 제공하는 것을 목적으로 한다.In particular, the present invention aims to provide a composition that is effective in preventing and treating respiratory diseases as an aroma treatment using extracts of natural substances rather than synthetic substances.
특히, 본 발명은 다양한 천연물질의 추출물을 혼합한 향을 이용한 호흡기 질환 예방 및 치료 효과가 있는 조성물을 제공하는 것을 목적으로 한다.In particular, the purpose of the present invention is to provide a composition effective in preventing and treating respiratory diseases using a scent mixed with extracts of various natural substances.
본 발명은 사이프러스 에센셜 오일을 포함하는, 향을 통해 폐렴을 포함하는 호흡기 질환을 예방 및 치료하는 천연 에센셜 복합오일을 제공하되, 사이프러스 에센셜 오일의 제1 에센셜 오일 성분; 및 라벤더 에센셜 오일(lavender essential oil), 유칼립투스 에센셜 오일(eucalyptus essential oil), 로즈마리 에센셜 오일(rosemary essential oil), 저먼 카모마일 에센셜 오일(German chamomile essential oil) 및 소량의 감귤계열(citrus) 에센셜 오일의 제2 에센셜 오일 성분 5종을 더 포함할 수 있다.The present invention provides a natural essential complex oil for preventing and treating respiratory diseases, including pneumonia, through fragrance, comprising cypress essential oil, comprising: a first essential oil component of cypress essential oil; and preparations of lavender essential oil, eucalyptus essential oil, rosemary essential oil, German chamomile essential oil and a small amount of citrus essential oil. 2 May contain 5 more essential oil ingredients.
또한, 본 발명에서 제1 에센셜 오일 100 중량부에 대하여 제2 에센셜 오일은 1 ~ 100 중량부를 사용할 수 있다.Additionally, in the present invention, 1 to 100 parts by weight of the second essential oil can be used based on 100 parts by weight of the first essential oil.
또한, 상기 복합오일은 방향제, 방향스틱, 방향스프레이, 향수 등으로 제조될 수 있다.Additionally, the complex oil can be manufactured into air fresheners, scent sticks, scent sprays, perfumes, etc.
본 발명의 복합오일은 향 치료를 통해 비강 내 유해균을 감소시킴으로서, 폐렴 등의 호흡기 질환을 예방 및 치료할 수 있다. 특히, 실험을 통한 실제 적용 사례에서 본 발명의 복합오일의 향을 일정 기간 맡은 환자에서는 비강 내 유해균(Staphylococcus, Clostridium)의 높은 감소 효과를 나타냈다. The complex oil of the present invention can prevent and treat respiratory diseases such as pneumonia by reducing harmful bacteria in the nasal cavity through aroma treatment. In particular, in practical application cases through experiments, patients who smelled the complex oil of the present invention for a certain period of time showed a high reduction effect of harmful bacteria (Staphylococcus, Clostridium) in the nasal cavity.
본 발명은 사이프러스 에센셜 오일을 포함하는, 폐렴을 포함하는 호흡기 질환을 예방 및 치료하는 천연 에센셜 복합오일을 제공한다. 이하 본 발명의 복합오일을 "향기시료"라고 약칭하기로 한다. 본 발명의 복합오일은 향 치료용으로 사용되기에, 방향제, 방향스틱, 방향스프레이, 향수 등의 방향 제품으로 제조될 수 있다. The present invention provides a natural essential complex oil containing cypress essential oil for preventing and treating respiratory diseases, including pneumonia. Hereinafter, the complex oil of the present invention will be abbreviated as “fragrance sample.” Since the complex oil of the present invention is used for aroma treatment, it can be manufactured into fragrance products such as air fresheners, fragrance sticks, fragrance sprays, and perfumes.
본 발명은 사이프러스 에센셜 오일의 제1 에센셜 오일 성분과, 라벤더 에센셜 오일(lavender essential oil), 유칼립투스 에센셜 오일(eucalyptus essential oil), 로즈마리 에센셜 오일(rosemary essential oil), 저먼 카모마일 에센셜 오일(German chamomile essential oil) 및 소량의 감귤계열(citrus) 에센셜 오일의 제2 에센셜 오일 성분 5종을 더 포함할 수 있다. The present invention includes the first essential oil component of cypress essential oil, lavender essential oil, eucalyptus essential oil, rosemary essential oil, and German chamomile essential oil. ) and a small amount of 5 second essential oil components of citrus essential oil.
본 발명에서 제1 에센셜 오일은 제2 에센셜 오일에 비해 더 많이 포함하는 것이 바람직하다. 제2 에센셜 오일의 5종의 에센셜 오일은 동일 함량으로 사용해도 좋지만, 상황에 따라 비율을 달리할 수 있다. In the present invention, it is preferable that the first essential oil contains more than the second essential oil. The five essential oils of the second essential oil can be used in the same amount, but the ratio may vary depending on the situation.
본 발명에서 제1 에센셜 오일 100 중량부에 대하여 제2 에센셜 오일은 1 ~ 100 중량부를 사용할 수 있다. In the present invention, 1 to 100 parts by weight of the second essential oil can be used based on 100 parts by weight of the first essential oil.
향기시료의 비강 내 실험 방법Intranasal testing method for scent samples
본 발명에서는 총 14명의 연구대상자에 대한 연구를 완료하였고, 사이프러스 에센셜 복합오일을 이용한 향치료를 시행한 시험군 8명, 위약을 이용한 대조군은 6명이었다. 연구대상자의 평균연령은 73세였고, 남성 5명과 여성 9명으로 구성되었다. In the present invention, a study was completed on a total of 14 subjects, with 8 subjects in the test group receiving aromatherapy using cypress essential oil complex oil and 6 subjects in the control group using placebo. The average age of the study subjects was 73 years old and consisted of 5 men and 9 women.
비강 내 미생물체 분석과 인지 및 심리검사를 향 치료(혹은 위약 치료) 전과 4주 후 평가하였고, 2군의 효능 및 부작용을 비교분석하였다. 연구 중 부작용을 호소하는 연구대상자는 없었으며, 환자에게 향치료를 안전하게 사용할 수 있음을 확인할 수 있었다. 비강 내 미생물체 분석 결과 향 치료를 시행한 시험군에세 통계적으로 유의미하게 유해균을 감소시켰으므로, 상대적으로 유익한 균의 비율이 높아졌을 것으로 추정하였다. Nasal microorganism analysis and cognitive and psychological tests were evaluated before and 4 weeks after aroma treatment (or placebo treatment), and the efficacy and side effects of the two groups were compared and analyzed. There were no subjects who complained of side effects during the study, and it was confirmed that aromatherapy can be safely used on patients. As a result of the analysis of intranasal microorganisms, it was estimated that the proportion of beneficial bacteria was relatively increased because there was a statistically significant reduction in harmful bacteria in the test group that received scent treatment.
1) 향기시료(Cypress essential oil complex No.8) 또는 플라시보 시료가 담긴 용기의 뚜껑을 열었다. 1) Open the lid of the container containing the fragrance sample (Cypress essential oil complex No.8) or placebo sample.
상기 향기시료의 성분은 아래 표와 같다. The ingredients of the fragrance sample are listed in the table below.
2) 함께 나누어준 디퓨징 스틱을 용기에 꽂았다. 2) I inserted the diffuser stick that was provided into the container.
3) 환자가 적어도 하루에 3시간 이상 향기에 노출(exposure to Cypress essential oil complex over 3 hours a day)될 수 있는 공간을 선택했다. 예를 들어 환자가 잠을 자는 침실이나 환자가 생활하는 거실 등 독립된 공간이 가장 적합하다. 3) A space was selected where the patient could be exposed to the scent for at least 3 hours a day (exposure to Cypress essential oil complex over 3 hours a day). For example, an independent space such as a bedroom where the patient sleeps or a living room where the patient lives is most suitable.
4) 선택한 공간에 가급적 환자와 약 1m 정도의 거리를 두고 용기를 놓아두었다. 물론 불가피한 경우 가깝게 두거나 멀리 두어도 큰 영향은 없지만 1m 정도로 거리를 유지할 때 최적의 효과가 나타날 수 있기에 권고했다. 4) The container was placed in the selected space at a distance of approximately 1 m from the patient, if possible. Of course, if it is unavoidable, keeping them close or far away will not have a significant impact, but it is recommended that the optimal effect can be achieved when the distance is maintained at about 1m.
5) 나눠준 용기에 담긴 액체(Cypress essential oil complex)가 모두 증발하여 액체가 용기 바닥에서 0.5cm 이하로 남았을 경우, 새로운 시료 용기에 새로운 디퓨징 스틱을 꽂아 동일한 위치에 놓아두고 사용했다. 5) When all the liquid (Cypress essential oil complex) in the distributed container evaporated and less than 0.5 cm of liquid remained at the bottom of the container, a new diffusing stick was inserted into a new sample container and placed in the same location before use.
연구 대상자를 두 시험군(A/B)으로 나누어 그 중 한 시험군(A)에서는 사이프러스 에센셜 복합 오일 No.8(cypress essential oil complex No.8) 향기시료를 환자당 2개씩 나누어 주었다(시료의 사용방법은 별지로 나누어 준다.). 대조군(B)는 향기 농도가 1/100정도인 플라시보 시료를 2개씩 나누어 주었다. The study subjects were divided into two test groups (A/B), and in one test group (A), cypress essential oil complex No.8 fragrance samples were distributed to each patient (two samples per patient). Instructions for use are provided separately.) The control group (B) was given two placebo samples each with a scent concentration of about 1/100.
사이프러스 에센셜 복합 오일 시료 No.8은 위 표와 같이 총 6종의 천연 에센셜 오일로 구성된 액상의 물질로서 유리로 만들어진 용기에 담겨져 있다. 이하 이 시료 이름을 "향기시료"라고 부른다. Cypress essential oil complex oil sample No. 8 is a liquid substance composed of a total of 6 types of natural essential oils as shown in the table above and is contained in a glass container. Hereinafter, this sample is called “fragrance sample.”
향기시료의 주성분은 사이프러스 에센셜 오일로서 사이프러스는 지중해 전 지역에서 자생하는 측백나무과의 상록 거목으로서 기원전 2200년까지 거슬러 올라간 시점인 고대 이집트에서 '키위'라는 향수에 사용되었다는 기록이 전해진다. 향기시료에 사용된 6가지 천연 에센셜 오일은 짧게는 수백 년, 길게는 수천 년간 인류가 안전하게 사용해오고 있는 천연향료로서 오랜 기간 안전성이 검증되었기 때문에 임상시험 중 단순한 선호도에 따른 불편함과 같은 경미한 부작용 외에 특별한 위험성이나 위해요소는 없었다. 4주 동안 향기시료에 노출되도록 처치한 후 향기 치료 후 대상자 개개인의 배정군을 알지 못하는 연구자가 검사 시행 및 평가하도록 하였으며, 비강 내의 미생물의 변화를 측정하였다.The main ingredient of the scent sample is cypress essential oil. Cypress is a large evergreen tree of the Cupressaceae family that grows throughout the Mediterranean region. There are records that it was used in a perfume called 'Kiwi' in ancient Egypt as far back as 2200 BC. The six natural essential oils used in the fragrance samples are natural fragrances that have been safely used by humans for hundreds of years or thousands of years, and their safety has been verified for a long time. Therefore, in addition to minor side effects such as discomfort due to simple preference during clinical trials, There were no special risks or hazards. After exposure to the scent sample for 4 weeks, a researcher who did not know the assigned group of each subject performed the test and evaluated it after scent treatment, and measured changes in microorganisms in the nasal cavity.
실험 결과 : 비강 내 유해균 감소 실험Experiment result: Experiment to reduce harmful bacteria in the nasal cavity
위의 실험을 통한 병원균의 감소 효과를 실험한 결과는 아래와 같다.The results of testing the effect of reducing pathogens through the above experiment are as follows.
위 실험 결과, 속(Genus) 계열에서 병원균인 Staphylococcus(포도상구균) 속과 Clostridium 속에 대해 확인한 결과 Staphylococcus 속의 경우 위약군은 1.74%에서 1.11%로 감소하였으며, 시험군에서는 1.92%에서 0.62%로 위약군에 비해 큰 폭으로 감소가 되었다. 또한, Clostridium 속의 경우에도 위약군은 1.18%에서 1.16%로 변화가 없지만, 시험군은 1.33%에서 1.19%로 감소한 것을 알 수 있다. As a result of the above experiment, the genus Staphylococcus and Clostridium, which are pathogens in the Genus series, were confirmed. As a result, the genus Staphylococcus decreased from 1.74% to 1.11% in the placebo group, and from 1.92% to 0.62% in the test group compared to the placebo group. There was a significant decrease. In addition, in the case of Clostridium genus, there was no change from 1.18% to 1.16% in the placebo group, but it decreased from 1.33% to 1.19% in the test group.
특히, 종(species) 계열에서 Staphylococcus aureus 종이 위약군에 비해 시험군이 높은 비율로 감소하였으며, Streptococcus pneumoniae 종은 시험군에서 1.04%에서 0.87%로 감소된 반면 위약군에서는 0.94%에서 1.68%로 증가하였다. In particular, in the species series, Staphylococcus aureus species decreased at a higher rate in the test group compared to the placebo group, and Streptococcus pneumoniae species decreased from 1.04% to 0.87% in the test group, while it increased from 0.94% to 1.68% in the placebo group.
즉, 비강 내 미생물체 분석 결과 향 치료 후 시험군에서 비강 내 유해균의 비율이 큰 폭으로 감소했다. 위약군에 비해 통계적으로 유의하게 감소함으로써, 향 치료가 비강 내 유해균을 효과적으로 감소시키고, 상대적으로 유익한 균의 비율을 높여 줄 것으로 추정할 수 있다. In other words, as a result of the analysis of intranasal microorganisms, the proportion of harmful bacteria in the nasal cavity decreased significantly in the test group after incense treatment. Due to the statistically significant decrease compared to the placebo group, it can be assumed that scent treatment effectively reduces harmful bacteria in the nasal cavity and relatively increases the proportion of beneficial bacteria.
Claims (3)
사이프러스 에센셜 오일의 제1 에센셜 오일 성분; 및
라벤더 에센셜 오일(lavender essential oil), 유칼립투스 에센셜 오일(eucalyptus essential oil), 로즈마리 에센셜 오일(rosemary essential oil), 저먼 카모마일 에센셜 오일(German chamomile essential oil) 및 감귤계열(citrus) 에센셜 오일의 제2 에센셜 오일 성분을 포함하는,
비강 내 유해 미생물을 감소시켜 폐렴을 포함하는 호흡기 질환을 예방 및 치료하는 천연 에센셜 복합오일.
It is a natural essential complex oil that prevents and treats respiratory diseases, including pneumonia, by reducing harmful microorganisms in the nasal cavity through scent.
A first essential oil component of cypress essential oil; and
Secondary essential oils of lavender essential oil, eucalyptus essential oil, rosemary essential oil, German chamomile essential oil and citrus essential oil containing ingredients,
A natural essential oil complex that prevents and treats respiratory diseases, including pneumonia, by reducing harmful microorganisms in the nasal cavity.
비강 내 유해 미생물을 감소시켜 폐렴을 포함하는 호흡기 질환을 예방 및 치료하는 천연 에센셜 복합오일.
In claim 1, the second essential oil is contained in an amount of 1 to 100 parts by weight based on 100 parts by weight of the first essential oil.
A natural essential oil complex that prevents and treats respiratory diseases, including pneumonia, by reducing harmful microorganisms in the nasal cavity.
비강 내 유해 미생물을 감소시켜 폐렴을 포함하는 호흡기 질환을 예방 및 치료하는 천연 에센셜 복합오일.In claim 1, the complex oil is manufactured as a fragrance, fragrance stick, fragrance spray, or perfume formulation,
A natural essential oil complex that prevents and treats respiratory diseases, including pneumonia, by reducing harmful microorganisms in the nasal cavity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220163091 | 2022-11-29 | ||
| KR1020220163091 | 2022-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240080149A true KR20240080149A (en) | 2024-06-05 |
Family
ID=91470268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230167512A KR20240080149A (en) | 2022-11-29 | 2023-11-28 | natural essential oil composition for preventing and treating respiratory diseases by reducing intranasal hazardous microorganism |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20240080149A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100055030A (en) | 2008-11-17 | 2010-05-26 | 안국약품 주식회사 | Composition containing a herbal extract for preventing and treating respiratory organ disease |
| KR20140131409A (en) | 2013-05-02 | 2014-11-13 | 동국대학교 경주캠퍼스 산학협력단 | Composition comprising complex extract of Astragalus membranaceus BUNGE, Saposhnikovia divaricata Schiskin, Ostericum koreanum Maximowicz, Scutellaria baicalensis Georgi and Atractylodes japonica Koidz for preventing or treating asthma, bronchitis or pneumonia |
| KR20210042033A (en) | 2019-10-08 | 2021-04-16 | 한국식품연구원 | Composition for improving respiratory disease comprising Epilobium angustifolium extract as an active ingredient |
| KR20220093743A (en) | 2020-12-28 | 2022-07-05 | 재단법인 금산인삼약초산업진흥원 | Composition comprising Panax ginseng extract and Perilla frutescens leaves extract for preventing, ameliorating or treating of respiratory diseases caused by fine dust |
-
2023
- 2023-11-28 KR KR1020230167512A patent/KR20240080149A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100055030A (en) | 2008-11-17 | 2010-05-26 | 안국약품 주식회사 | Composition containing a herbal extract for preventing and treating respiratory organ disease |
| KR20140131409A (en) | 2013-05-02 | 2014-11-13 | 동국대학교 경주캠퍼스 산학협력단 | Composition comprising complex extract of Astragalus membranaceus BUNGE, Saposhnikovia divaricata Schiskin, Ostericum koreanum Maximowicz, Scutellaria baicalensis Georgi and Atractylodes japonica Koidz for preventing or treating asthma, bronchitis or pneumonia |
| KR20210042033A (en) | 2019-10-08 | 2021-04-16 | 한국식품연구원 | Composition for improving respiratory disease comprising Epilobium angustifolium extract as an active ingredient |
| KR20220093743A (en) | 2020-12-28 | 2022-07-05 | 재단법인 금산인삼약초산업진흥원 | Composition comprising Panax ginseng extract and Perilla frutescens leaves extract for preventing, ameliorating or treating of respiratory diseases caused by fine dust |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101884801B (en) | Air freshener and preparation method and application thereof | |
| Bağdat et al. | The essential oil of lemon balm (Melissa officinalis L.), its components and using fields | |
| CN104295055A (en) | Health-care type floor material with anion releasing function | |
| CN106266685B (en) | A kind of compound essential oil and preparation method thereof | |
| Shittu et al. | Antibacterial and antifungal activities of essential oils of crude extracts of Sesame radiatum against some common pathogenic micro-organisms | |
| CN104336078A (en) | Chlorine-containing Chinese herbal medicine air disinfectant, and preparation method and application thereof | |
| KR20110000216A (en) | Composition for aromatic containing extracts of pine needlesand, artemisia, green tea leaves and the manufacturing method thereof | |
| CN112075459A (en) | Antiviral and antibacterial respiratory tract compound essential oil and preparation method thereof | |
| CN103948954A (en) | Traditional Chinese medicine air purifier | |
| CN106265148A (en) | A kind of perfume containing natural plant essential oils and preparation method thereof | |
| CN116271166A (en) | Volatile oil aromatherapy antibacterial tablet and preparation method and application thereof | |
| RU2452470C1 (en) | Liposome suspension composition for prevention and treatment of respiratory infections, particularly tuberculosis (versions) and method of aerogene delivery thereof | |
| KR20210005666A (en) | Basic composition for producing biologically active agent | |
| KR101514240B1 (en) | Aromatheraphy Solution Oil Anti-Bac Composition and Processing make the same | |
| JP3849002B2 (en) | Essential oils for aromatherapy and methods of use | |
| KR100843692B1 (en) | Aromatic composition for rest, and solid perfume with it | |
| CN104758322A (en) | Composition capable of expelling insects, killing bacteria, sterilizing, and relieving nerve, and applications thereof | |
| KR20240080149A (en) | natural essential oil composition for preventing and treating respiratory diseases by reducing intranasal hazardous microorganism | |
| KR20120025740A (en) | Natural anti-bacterial composition and spray solution containing the same | |
| CN105613610A (en) | Air refreshing agent | |
| KR101632866B1 (en) | Composition containing natural herbs essential for removing endocrine disrupting chemicals and smoking method | |
| Lis-Balchin et al. | A study of the changes in the bioactivity of essential oils used singly and as mixtures in aromatherapy | |
| KR100843689B1 (en) | Aromatic composition for good mood, and solid perfume with it | |
| CN101473857B (en) | Chinese medicine environmental medical science treating agent first medical preparation | |
| CN106804584A (en) | Long effective air freshener |